Trial Profiles

Trial Profiles

Study of Regorafenib as a 3rd-line or
Greater Treatment for Gastrointestinal Stromal Tumors (GIST) (GRID)

A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care versus placebo plus best supportive care for patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with at least imatinib (Glivec®) and sunitinib (Sutent®).

Bayer HealthCare has announced the launch of a Phase III clinical trial (to be called the GRID trial) to evaluate the investigational compound regorafenib (BAY 73-4506) as a potential treatment option for patients diagnosed with gastrointestinal stromal tumors (GIST). More specifically, the GRID trial will evaluate the efficacy and safety of regorafenib in patients with metastatic and/or unresectable GIST who have progressed following treatment with imatinib and sunitinib.

As you may be aware, there are limited treatment options available to GIST patients whose disease has progressed following treatment with imatinib and sunitinib. Bayers’s goal with this trial is to determine if it will be possible to provide regorafenib as a safe and effective treatment option for these patients.

Approximately 170 patients from 18 countries around the world will be enrolled. In the trial, patients will be randomized in a 2:1 ratio to receive either regorafenib 160 mg once daily, 3 weeks on/1 week off, or else a placebo, and it will be double blinded such that neither patients nor physicians will know who is on the drug. However, patients on placebo who have progression will be allowed to cross over to the treatment arm.

The primary endpoint of this trial is progression-free survival (PFS), and secondary endpoints include overall survival (OS), time to progression (TTP), disease control rate (DCR), tumour response rate (RR), duration of response (DOR), and safety. All patients will enter the Survival Follow-Up Period upon discontinuation of study treatment, during which assessment of survival status will be performed every three months. Patients who respond to regorafenib will be allowed to stay on treatment indefinitely.

Bayer recognises there may be concern about the placebo arm of the trial, and explains: “We implemented this design in order to establish the safety and efficacy of regorafenib in this specific patient population, for which there is no existing standard of care. While we recognize that patients who are randomized into the placebo arm may not benefit from being included in this trial at first, it is important to note that the study design includes a “cross-over” procedure, for which patients who were treated with placebo will have the option to begin treatment with regorafenib after tumour progression. Again, our ultimate goal with this Phase III trial is to establish the safety and efficacy of regorafenib in this specific patient setting. The trial was carefully designed in an effort to reach this goal.”

Some background information: Regorafenib is an investigational, potent oral multi-kinase inhibitor of angiogenic, stromal and oncogenic (receptor tyrosine) kinases (TK). Regorafenib inhibits angiogenic kinases like receptors for VEGF and the TIE2 receptor which play central roles in angiogenesis. It also inhibits various oncogenic kinases including RAF, RET and c-KIT, thereby helping to stop the proliferation of cancer cells.

Regorafenib has shown potent antitumor activity in preclinical studies by inhibiting tumour growth in multiple xenograft models via antiangiogenic and antiproliferative mechanisms. Based on these results, regorafenib is currently being investigated in clinical trials for its potential to treat patients with various tumor types. Clinical activity of regorafenib was recently shown in Phase I and II clinical studies in a variety of tumour types.

Registered sites (expert centres) for the trial in Europe are:

Austria: Graz, Innsbruck, Wien
Belgium: Edegem, Leuven
Finland: Helsinki, Oulu
France: Bordeaux, Lyon, Marseille
Germany: Mannheim, Tübingen, Bad Saarow, Hannover, Essen, Köln
Israel: Beer Sheva, Tel Aviv
Italy: Rozzano, Candiolo, Bari, Bologna, Firenze, Milano, Palermo
Netherlands: Leiden
Poland: Warszawa
Spain: Barcelona, Madrid, Valencia
Switzerland: Zürich
United Kingdom: Cambridge, Leicester, London, Manchester


The GRID-Trial in facts figures:

Sponsor: Bayer
Identifier: NCT01271712

GRID = "GIST: Regorafenib In Progressive Disease"

Drug: Regorafenib (BAY 73-4506) and placebo
Phase: III
Line: Thirdline (after Imatinib and Sunitinib)
Dosing: 160 mg/day (4 units 40mg each)
3 weeks of every 4 week (28 day) cycle (3 weeks on/1 week off)
Tumour assessment:

every 4 weeks for the first 3 months

every 6 weeks for the next 3 months (through month 6)

every 8 weeks until the end of treatment

or more frequently if clinically indicated

Estimated Enrollment: 170 patients (in 18 countries)
Ages Eligible for Study: 18 Years and older
Study Start Date: January 2011
Estim. Completion Date:
January 2013
Please note: Regorafenib is an investigational agent and
is not approved by EMA, FDA or other Health Authorities.




Member LogIn